<DOC>
	<DOCNO>NCT02821624</DOCNO>
	<brief_summary>This first-in-human ( FIH ) study provide first safety pharmacokinetic ( PK ) data G1T38 human allow development G1T38 patient cancer .</brief_summary>
	<brief_title>First-in-Human Safety , PK , Food Effect Study Single Ascending Doses G1T38 Healthy Volunteers</brief_title>
	<detailed_description />
	<criteria>Healthy male female volunteer , 4065 year age ; clinically significant finding report follow detailed physical examination , medical history , vital sign , clinical laboratory test , ECGs deem PI Body mass index ( BMI ) range 18 32 kg/m2 ( inclusive ) screening , weigh least 50 kg Nonusers nicotinecontaining product least previous 3 month prior dose nonsmoker Agreement use birth control study 3 month post last visit . Able comply protocol requirement procedures Clinically significant abnormality find physical examination , medical history review , ECGs ( QTcF interval &gt; 450 millisecond male &gt; 470 millisecond female ) , vital sign , laboratory test ( include positive HIV , hepatitis B C ) Participated previous clinical study investigational product last 60 day History serious allergic reaction medication Any blood plasma donation loss blood volume exceed 500 mL within 3 month dose History drug alcohol abuse last 2 year Pregnant lactating woman Any issue , opinion PI , make subject ineligible study participation</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>